Danuta Gąsior‐Perczak

The impact of BMI on clinical progress, response to treatment, and disease course in patients with differentiated thyroid cancer

Danuta Gąsior‐Perczak, Iwona Pałyga, Monika Szymonek et al. · PLoS ONE · 2018 · 44 citations · Full text

Medicine, Endocrinology, Oncology +14

Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer

Tomasz Trybek, Agnieszka Walczyk, Danuta Gąsior‐Perczak et al. · Endocrinology · 2019 · 42 citations · Full text

Medicine, Molecular Genetics, Oncology +16

The Delayed Risk Stratification System in the Risk of Differentiated Thyroid Cancer Recurrence

Aldona Kowalska, Agnieszka Walczyk, Iwona Pałyga et al. · PLoS ONE · 2016 · 29 citations · Full text

Medicine, Oncology, Early Detection +14

The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer

Aldona Kowalska, Iwona Pałyga, Danuta Gąsior‐Perczak et al. · PLoS ONE · 2015 · 27 citations · Full text

Medicine, Endocrinology, Oncology +16

Immunohistochemistry cannot replace DNA analysis for evaluation of<i>BRAF</i>V600E mutations in papillary thyroid carcinoma

Monika Szymonek, Artur Kowalik, Janusz Kopczyński et al. · Oncotarget · 2017 · 25 citations · Full text

Medicine, Oncology, Pathology +17